- Home
- ADSE vs ANNX Comparison
ADSE vs ANNX Comparison
Compare ADSE & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- ANNX
- Stock Information
- Founded
- ADSE 1980
- ANNX 2011
- Country
- ADSE Ireland
- ANNX United States
- Employees
- ADSE N/A
- ANNX N/A
- Industry
- ADSE Industrial Specialties
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- ANNX Health Care
- Exchange
- ADSE Nasdaq
- ANNX Nasdaq
- Market Cap
- ADSE 728.1M
- ANNX 668.8M
- IPO Year
- ADSE N/A
- ANNX 2020
- Fundamental
- Price
- ADSE $13.24
- ANNX $6.12
- Analyst Decision
- ADSE Hold
- ANNX Strong Buy
- Analyst Count
- ADSE 1
- ANNX 7
- Target Price
- ADSE $14.00
- ANNX $15.80
- AVG Volume (30 Days)
- ADSE 93.5K
- ANNX 1.2M
- Earning Date
- ADSE 09-12-2024
- ANNX 11-14-2024
- Dividend Yield
- ADSE N/A
- ANNX N/A
- EPS Growth
- ADSE N/A
- ANNX N/A
- EPS
- ADSE N/A
- ANNX N/A
- Revenue
- ADSE $158,974,606.00
- ANNX N/A
- Revenue This Year
- ADSE $98.67
- ANNX N/A
- Revenue Next Year
- ADSE $47.66
- ANNX N/A
- P/E Ratio
- ADSE N/A
- ANNX N/A
- Revenue Growth
- ADSE 168.42
- ANNX N/A
- 52 Week Low
- ADSE $6.10
- ANNX $2.27
- 52 Week High
- ADSE $15.01
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- ADSE 43.56
- ANNX 30.04
- Support Level
- ADSE $13.18
- ANNX $6.85
- Resistance Level
- ADSE $14.33
- ANNX $7.63
- Average True Range (ATR)
- ADSE 0.70
- ANNX 0.32
- MACD
- ADSE -0.14
- ANNX -0.17
- Stochastic Oscillator
- ADSE 14.58
- ANNX 6.22
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.